INTRODUCTION AND OBJECTIVES: Following the results of the TOPARP-A Phase II trial, Olaparib, an oral PARP inhibitor was recently recognized as a FDA breakthrough therapy for metastatic castration recurrent prostate cancer (mCRPC) patients who have germline mutations in DNA repair genes. Although these results are noteworthy, the problem remains of how to treat the remaining mCRPC patients who do not have detectable germline mutations of DNA repair genes. Androgen receptor (AR) signaling regulates DNA repair in prostate cancer and AR modulating drugs induce DNA damage. Thus a combination approach using AR modulating drugs with a PARP inhibitor could be a promising option for the treatment of mCRPC. All currently approved AR modulating drugs, such as enzalutamide and abiraterone, either directly or indirectly target the AR C-terminus ligand-binding domain (LBD). Such drugs are often unsuccessful due to the emergence of AR splice variants (ARV-7, ARv567es) that are constitutively active and lack a LBD. EPI-002 is a first-in-class AR antagonist that targets both full-length AR and AR splice variants. Here we present data to support that a combination of Olaparib, a PARP inhibitor, and EPI-002 have beneficial effects in vitro.
INTRODUCTION AND OBJECTIVES: Following the results of the TOPARP-A Phase II trial, Olaparib, an oral PARP inhibitor was recently recognized as a FDA breakthrough therapy for metastatic castration recurrent prostate cancer (mCRPC) patients who have germline mutations in DNA repair genes. Although these results are noteworthy, the problem remains of how to treat the remaining mCRPC patients who do not have detectable germline mutations of DNA repair genes. Androgen receptor (AR) signaling regulates DNA repair in prostate cancer and AR modulating drugs induce DNA damage. Thus a combination approach using AR modulating drugs with a PARP inhibitor could be a promising option for the treatment of mCRPC. All currently approved AR modulating drugs, such as enzalutamide and abiraterone, either directly or indirectly target the AR C-terminus ligand-binding domain (LBD) . Such drugs are often unsuccessful due to the emergence of AR splice variants (ARV-7, ARv567es) that are constitutively active and lack a LBD. EPI-002 is a first-in-class AR antagonist that targets both full-length AR and AR splice variants. Here we present data to support that a combination of Olaparib, a PARP inhibitor, and EPI-002 have beneficial effects in vitro.
METHODS: Combination therapy using EPI-002 and Olaparib were evaluated in vitro using human prostate cancer cells, LNCaP (androgen sensitive and expresses full-length AR) and LNCaP95, an androgen-independent cell line that expresses full-length AR and AR-V7 and is resistant to enzalutamide. The effects of monotherapy and combination therapy on cell cycle and DNA damage were analysed using FACS and Western blot.
RESULTS: Unexpectedly, EPI-002 caused an enormous decrease of Checkpoint kinase 1 (Chk1) protein levels in LNCaP and LNCaP95 cells. Chk1 is one of the important mediators in cell cycle checkpoint during the DNA damage response. Whereas, enzalutamide also decreased the expression of Chk1 in LNCaP, it had no effect on Chk1 levels in LNCaP95 cells. Consistent with these data, AR knockdown in LNCaP cells also decreased Chk1 levels. The PARP inhibitor, Olaparib, induced phosphorylation of Chk1. EPI-002 induced G1 cell cycle arrest whereas Olaparib induced G2/M cell cycle arrest. FACS analysis of gH2AX showed increased DNA damage with combination therapy compared to monotherapies.
CONCLUSIONS: EPI-002 decreased the expression of Chk1 in prostate cancer cells that expressed both full-length AR and AR-V7. Combination therapy of EPI-002 plus Olaparib may provide a therapeutic approach for prostate cancer that expresses AR-V7. 
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INTRODUCTION AND OBJECTIVES:
Multiple androgen receptor (AR) dependent and independent resistance mechanisms limit the efficacy of current castration resistant prostate cancer (CRPC) treatment modalities. EPI-001 is a novel N-terminal domain (NTD) binding AR targeting component with the promising ability to block constitutively active splice variants; a major resistance mechanism in CRPC. Autophagy a conserved lysosomal degradation pathway, is a survival mechanism in cells exposed to anti-cancer treatment. We hypothesized that also a promising NTD-AR treatment may lead to upregulation of autophagy, which can be targeted by a combination therapy with autophagy inhibitors.
METHODS: The human prostate cancer cell line LNCaP was cultured in steroid-free medium. Cells were treated with different concentrations of EPI-001 (10, 25, 50uM) and in combination with autophagy inhibitors chloroquine (CHQ, 20uM) or 3-methyladenine (3MA, 5mM). Viability was assessed by WST-1-assays after 1, 3 and 7 days. AnnexinV and Propidium Iodide were used to measure apoptosis and necrosis on day 7 after treatment. Autophagic activity was monitored on protein levels by western blot (WB) and immunocytochemistry for the expression of LC3-I/II, Atg5 and Beclin1. In addition, autophagosome increase was detected by Autodot staining.
RESULTS: Treatment with EPI-001 resulted in a dose dependent reduction of cell viability up to 50% with 50uM EPI-001 on day 7. At the same time apoptosis increased by 11.53% and necrosis by 3.74% compared to the control. Combination of 50 uM EPI-001 with autophagy inhibitors led to a further significant reduction of cell viability up to 40% for CHQ and 28% for 3MA. Assessment of autophagy levels in EPI-001 treated cells by WB showed an increase of LC3-II in a dose dependent manner. No Change in Beclin1 expression was seen. Immuncytochemistry detected a significant increase of Atg5 and pronounced LC3-II punctuation in EPI-001 treated cells. This was supported by an increase in autophagosome punctuation observed by Autodot staining.
CONCLUSIONS: Our data demonstrate that the treatment with EPI-001 leads to increased autophagic activity in LNCaP prostate cancer cells. Combination of N-terminal androgen receptor blockage with simultaneous autophagy inhibition increases the antitumor effect of EPI-001 in vitro. This may offer a promising strategy to overcome resistance mechanisms in castration resistant prostate cancer.
The anti-diabetic drug metformin (MET) and the anti-epileptic drug sodium valproate (VPA), when used alone, have shown anti-cancer effects in prostate cancer (PCa). However high doses are required which results in unacceptable toxicity. Here, we aimed to determine if the combination of MET and VPA (MET+VPA) at clinically relevant doses would (1) induce a synergistic anti-tumor effect in human PCa cell lines and patient-derived PCa explants, (2) cause minimal toxicity to normal tissues in vivo, (3) identify prognostic molecular markers for MET+VPA responses and (4) lead to rapid clinical application.
METHODS: Human PCa cell lines (PC-3 and LNCaP) and radical prostatectomy explants from 8 patients were analyzed for response to MET+VPA. Ki67, cleaved caspase-3, the androgen receptor (AR), and p53 expression in explants were analyzed using immunohistochemistry. The combinatorial effects of MET+VPA were calculated using the Drug Combination Index (CI). The role of p53 and AR in response to MET+VPA was determined using TP53 gene knockdown in LNCaP and TP53 ectopic expression in PC3, and AR was chemically inhibited using Enzalutamide in LNCaP. The toxicity of MET+VPA was determined using histological scoring systems for kidney and liver toxicity in nude mice.
RESULTS: MET+VPA synergistically inhibited proliferation in both PC-3 and LNCaP and synergistically induced apoptosis in LNCaP cells (CI<0.9). All PCa explants (pathological stage pT2C-pT3A and e1108
THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 Gleason score 7-9) demonstrated a significant reduction (90%, p<0.001) in proliferation and a significant dose-dependent increase in apoptosis (300%, p<0.001) compared to vehicle. The p53 protein plays a role in MET+VPA as depletion of TP53 in LNCaP significantly reduced the apoptotic response by 58% (p¼0.001) and the ectopic expression of TP53 in PC3 significantly increased the apoptotic response by 15% (p¼0.047). The AR signaling pathway was also confirmed to play an important role in the apoptotic response to MET+VPA as Enzalutamide significantly reduced apoptosis by 28.5% (p¼0.029) in LNCaP cells. No kidney or liver toxicity was detected in nude mice after 8 weeks administration of MET+VPA. These results support evaluation in a Phase I clinical trial which will start early in 2017 (Trial ID: ACTRN12616001021460p). CONCLUSIONS: Our study has only taken 2 years from the first experiment to a phase I clinical trial. Although MET+VPA with an AR inhibitor may not show benefit, MET+VPA has potential to control clinically localized or metastatic PCa, particularly in tumors with functional p53 and/or AR signaling. 
MP83-09 ELUCIDATING CROSS-RESISTANCE BETWEEN DOCETAXEL AND CABAZITAXEL IN CASTRATION RESISTANT PROSTATE CANCER
Alan Lombard, Chengfei Liu, Cameron Armstrong, Wei Lou, Christopher Evans, Allen Gao*, Sacramento, CA INTRODUCTION AND OBJECTIVES: Castration resistant prostate cancer (CRPC) is an incurable disease with few durable treatment options. Understanding the mechanisms of disease resistance will allow for the creation of more efficacious therapeutic options. Cabazitaxel is a next-generation taxane drug which is approved for the treatment of CRPC post docetaxel. However, cabazitaxel leads only to a modest survival benefit underlying the need to better understand the mechanisms of resistance to this drug. Whether there exists crossresistance between docetaxel and cabazitaxel in the CRPC setting is unknown. Here we sought to investigate whether docetaxel resistance leads to the development of cabazitaxel resistance and how this effect may be mediated.
METHODS: TaxR and DTXR docetaxel-resistant cell line derivatives were created by chronically exposing C4-2B and DU145 cells respectively to increasing doses of docetaxel. Cell growth assays utilizing a coulter cell counter to attain cell numbers were used to assess cellular response to treatment. Colony formation assays were used to support cell growth assay data. Apoptosis was assessed using western blots for cleaved-PARP. TaxR cells stably expressing a plasmid containing a shRNA targeting ABCB1 were used to test the role of ABCB1 in mediating resistance to cabazitaxel.
RESULTS: Cell growth and colony formation assays demonstrated that docetaxel resistant prostate cancer cells are cross-resistant to cabazitaxel. We further show that apoptosis is blunted in docetaxel resistant cells in response to cabazitaxel treatment. Interestingly, both resistant cell lines were completely resistant to high dose docetaxel. Our previous work showed that increased expression of ABCB1 was largely responsible for mediating resistance to docetaxel. Thus, we sought to test whether this would alter cellular response to cabazitaxel. Using either a shRNA to decrease the expression of ABCB1 or elacridar, a small molecule inhibitor of ABCB1, re-sensitizes these cells to cabazitaxel treatment and restores the cell death response. We additionally show that inhibition of ABCB1 function using the anti-androgen drugs bicalutamide and enzalutamide effectively re-sensitizes cells to cabazitaxel treatment. CONCLUSIONS: Our work suggests that docetaxel and cabazitaxel resistance is mediated by similar mechanisms. Evidence from other groups demonstrates that cabazitaxel is a better drug in the predocetaxel setting. This in conjunction with our work indicates that it may be more beneficial to move cabazitaxel into the docetaxel treatment space. Our study also highlights the potential of combination therapies with anti-androgen drugs to enhance cabazitaxel effectiveness in the docetaxel resistant setting.
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MP83-10 CORRELATION BETWEEN CABAZITAXEL RESISTANCE AND EMT IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Hiroshi Hongo*, Takeo Kosaka, Yota Yasumizu, Yasumasa Miyazaki, Eiji Kikuchi, Akira Miyajima, Mototsugu Oya, Tokyo, Japan INTRODUCTION AND OBJECTIVES: Recently, cabazitaxel (CBZ) was identified as the most effective cytotoxic agent to demonstrate an improvement in survival in men with docetaxel-refractory CRPC. Accumulating evidence suggests EMT induced by androgendeprivation therapy or docetaxel explains in part the aggressiveness of CRPC. The aim of this study was to screen for EMT inhibitory drugs by bioinformatic analysis and exploring the antitumor effect of CBZ for resistant CRPC.
METHODS: PC3 and DU145 were used in this study. We incubated the cell lines with gradually increasing concentrations of CBZ to establish CBZ-resistant cell lines. In addition, we performed screening tests for candidate drugs to inhibit EMT of metastatic CRPC. The combined effect of CBZ and a candidate EMT inhibitor for CBZresistant cell lines was determined using a cell viability assay.
RESULTS: We established a CBZ-resistant cell line, PC3-CBZR (Figure) . PC3-CBZR cells underwent cell division with 3 nM CBZ. We compared the cytotoxic effect of CBZ on PC3 and PC3-CBZR cells using a cell viability assay. The IC50 of CBZ in PC3 and PC3-CBZR cells were 16.0 nM and 2.5 nM, respectively. Real-time PCR showed up-regulation of ZEB family and Vimentin and downregulation of E-cadherin expression, suggesting PC3-CBZR cells had elevated metastatic potential. We screened for EMT inhibitors using The Broad institute 0 s connectivity map (CMAP) analysis, with human whole genome array data and identified a candidate drug, KOH513. The relative cell viabilities treated with 10 mM KOH513 in PC3 and PC3-CBZR cells were 60.0 AE 1.7%, 58.7 AE 0.7%, respectively. KOH513 was suggested to have an antitumor effect on CBZ-resistant prostate cancer. Real time PCR and immune fluorescence assay showed that KOH513 down-regulated ZEB family and Vimentin in PC3-CBZR cells at the protein and mRNA levels. We tested the efficacy of KOH513 in CBZ resistance using a cell viability assay. Single-agent administration of 6 nM CBZ or 3 mM KOH513 did not have an antitumor effect in PC3-CBZ cells. However, when treated with 6 nM CBZ and 3 mM KOH513 in combination, PC3-CBZ cell proliferation was significantly suppressed (relative cell viability 77.0 AE 1.7%). In the same manner, we established CBZ-resistant DU145 cells, DU145-CBZR. DU145-CBZR cells had also had an upregulated EMT pathway, and cell proliferation was suppressed by EMT inhibitor KOH513. These results suggested that KOH513 had potential for reprogramming CBZ resistant CRPC cell lines into sensitive cell lines.
CONCLUSIONS: Targeting EMT signaling pathways with KOH513 can overcome CBZ resistance in CRPC.
